Streetbeat News

AKTX

Akari Therapeutics, Plc

https://www.akaritx.com

Industry

Biotechnology

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Akari Therapeutics announced the implementation of a workforce reduction of approximately 67% starting May 1, as disclosed in their 8-K filing.

Portfolio Pulse from Charles Gross

May 07, 2024 | 9:08 pm

Akari Therapeutics and Peak Bio have announced a portfolio prioritization plan following their merger. The plan focuses on advancing Peak's ADC cancer therapeutic platform and Akari's PAS-nomacopan for Geographic Atrophy. Additionally, Akari Therapeutics has announced leadership changes.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 12:08 pm

In Tuesday's after-market session, several healthcare stocks showed significant movement. Predictive Oncology led the gainers with a 36.4% increase, while Concord Medical Services experienced the largest drop, declining by 23.3%. Notably, TransMedics Group and CVRx reported their Q1 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 8:31 pm

Akari Therapeutics announced it will present pre-clinical electroretinography data for PAS-Nomacopan at ARVO 2024. This presentation could highlight potential advancements in their research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:07 pm

Akari Therapeutics shares are trading lower following the announcement of their FY23 financial results.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 5:49 pm

Akari Therapeutics reported a cash position of approximately $3.8M as of December 31, 2023. In March 2024, the company raised around $2M through a private placement and plans to secure more capital in Q2 of 2024.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 10:35 am

Akari Therapeutics reported a Fiscal Year 2023 Earnings Per Share (EPS) of $0.00, which remained unchanged from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 10:34 am

Akari Therapeutics and Peak Bio have announced a merger of equals. The exchange terms suggest that Akari shareholders and Peak stockholders will each own approximately 50% of the combined company.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:03 pm

Akari Therapeutics has completed a private placement with current investors, raising approximately $2 million in gross proceeds. This capital infusion is expected to support the company's ongoing operations and development projects.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:01 pm

Akari Therapeutics, Plc (NASDAQ:AKTX) announced that its Chief Scientific Officer will present a poster on the development of PASylated®-Nomacopan for Treatment of Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development conference. The long-acting PAS-nomacopan is in the final stages of pre-clinical development as a potential treatment for GA.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:49 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.